HRP20041238A2 - Use of cetp inhibitors and optionally hmg coa redught hyaluronic acid formulation - Google Patents
Use of cetp inhibitors and optionally hmg coa redught hyaluronic acid formulationInfo
- Publication number
- HRP20041238A2 HRP20041238A2 HR20041238A HRP20041238A HRP20041238A2 HR P20041238 A2 HRP20041238 A2 HR P20041238A2 HR 20041238 A HR20041238 A HR 20041238A HR P20041238 A HRP20041238 A HR P20041238A HR P20041238 A2 HRP20041238 A2 HR P20041238A2
- Authority
- HR
- Croatia
- Prior art keywords
- redught
- hyaluronic acid
- hmg coa
- cetp inhibitors
- acid formulation
- Prior art date
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 229920002674 hyaluronan Polymers 0.000 title 1
- 229960003160 hyaluronic acid Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39339502P | 2002-07-02 | 2002-07-02 | |
| PCT/IB2003/002792 WO2004004778A1 (fr) | 2002-07-02 | 2003-06-18 | Utilisation d'inhibiteurs cetp et eventuellement d'inhibiteurs de la hmg coa reductase et/ou d'agents anti-hypertensifs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20041238A2 true HRP20041238A2 (en) | 2005-06-30 |
Family
ID=30115572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20041238A HRP20041238A2 (en) | 2002-07-02 | 2004-12-30 | Use of cetp inhibitors and optionally hmg coa redught hyaluronic acid formulation |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20040053842A1 (fr) |
| EP (1) | EP1519754A1 (fr) |
| JP (1) | JP2005532388A (fr) |
| KR (1) | KR20050025578A (fr) |
| CN (1) | CN1665537A (fr) |
| AP (1) | AP2004003189A0 (fr) |
| AU (1) | AU2003244921A1 (fr) |
| BR (1) | BR0312421A (fr) |
| CA (1) | CA2488736A1 (fr) |
| EA (1) | EA200401471A1 (fr) |
| EC (1) | ECSP045520A (fr) |
| HR (1) | HRP20041238A2 (fr) |
| IL (1) | IL165328A0 (fr) |
| IS (1) | IS7570A (fr) |
| MA (1) | MA27311A1 (fr) |
| MX (1) | MXPA05000015A (fr) |
| NO (1) | NO20050497L (fr) |
| OA (1) | OA12876A (fr) |
| PL (1) | PL374878A1 (fr) |
| TN (1) | TNSN04268A1 (fr) |
| TW (1) | TW200401768A (fr) |
| WO (1) | WO2004004778A1 (fr) |
| ZA (1) | ZA200409582B (fr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| DE60323536D1 (de) * | 2002-12-20 | 2008-10-23 | Pfizer Prod Inc | Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer |
| CA2509688A1 (fr) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Formes posologiques comprenant un inhibiteur de la cetp et un inhibiteur de la hmg-coa reductase |
| US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
| KR20110010824A (ko) | 2003-01-14 | 2011-02-07 | 아레나 파마슈티칼스, 인크. | 대사 조절제로서의 １,２,３-삼치환된 아릴 및 헤테로아릴 유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된 장애의 예방 및 치료 |
| PL1603553T3 (pl) * | 2003-03-17 | 2012-04-30 | Japan Tobacco Inc | Kompozycje farmaceutyczne inhibitorów CETP |
| KR20050110017A (ko) * | 2003-03-17 | 2005-11-22 | 니뽄 다바코 산교 가부시키가이샤 | Ｓ-'２-(''１-(２-에틸부틸)시클로헥실!카르보닐!아미노)페닐!-２-메틸프로판티오에이트의 경구 생체이용율을증가시키는 방법 |
| TWI393560B (zh) * | 2003-05-02 | 2013-04-21 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| CA2526730A1 (fr) * | 2003-05-30 | 2004-12-09 | Ranbaxy Laboratories Limited | Derives pyrroliques substitues |
| JP4920410B2 (ja) | 2003-07-14 | 2012-04-18 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 代謝モジュレーターとしての縮合アリールおよびヘテロアリール誘導体ならびに代謝に関連する障害の予防および治療 |
| US20070275996A1 (en) * | 2003-12-16 | 2007-11-29 | Michele Bortolini | Use of Statins For The Treatment Of Metabolic Syndrome |
| MXPA06011540A (es) * | 2004-04-07 | 2007-01-26 | Millennium Pharm Inc | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias. |
| US20060063803A1 (en) * | 2004-09-23 | 2006-03-23 | Pfizer Inc | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds |
| WO2007115131A2 (fr) * | 2006-03-29 | 2007-10-11 | Guilford F Timothy | Combinaison de glutathion réduit liposomique et de 1-arginine, avec un ou plusieurs autres ingrédients, pouvant être administrée par plusieurs voies, permettant d'inverser et de prévenir l'obésité et de stimuler la biogenèse mitochondriale |
| CA2588216A1 (fr) * | 2004-11-22 | 2006-05-26 | Dexcel Pharma Technologies Ltd. | Formulations d'atorvastatine stables |
| CA2587791C (fr) * | 2004-12-06 | 2012-03-13 | Avigen, Inc. | Methode de traitement des douleurs neuropathiques et les syndromes associes |
| US7700774B2 (en) * | 2004-12-20 | 2010-04-20 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds and their pharmaceutical compositions |
| EP1833466A1 (fr) * | 2004-12-28 | 2007-09-19 | Ranbaxy Laboratories Limited | Procedes permettant de preparer des formes posologiques pharmaceutiques solides et stables a base d'atorvastatine et d'amlodipine |
| US8604055B2 (en) * | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| US9040558B2 (en) | 2004-12-31 | 2015-05-26 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| WO2007106111A2 (fr) * | 2005-07-01 | 2007-09-20 | Elan Pharma International Limited | Compositions nanoparticulaires et a liberation controlee comprenant de la nilvadipine |
| EP1948600B1 (fr) | 2005-07-05 | 2014-04-16 | The President & Fellows Of Harvard College | Conjugues cibles sur le foie |
| SG166829A1 (en) * | 2005-11-08 | 2010-12-29 | Ranbaxy Lab Ltd | Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
| AR059838A1 (es) * | 2006-03-14 | 2008-04-30 | Ranbaxy Lab Ltd | Formulaciones para dosis estabilizantes de estatina |
| WO2007116243A2 (fr) * | 2006-04-10 | 2007-10-18 | Mintails Limited | Procede de traitement de la fibromyalgie et de pathologies apparentees |
| BRPI0714361A2 (pt) * | 2006-07-14 | 2013-03-26 | Ranbaxy Lab Ltd | polimorfo cristalino, composiÇço farmacÊutica contendo o mesmo, mÉtodo para sua preparaÇço e mÉtodo de tratamento |
| PL2131841T3 (pl) * | 2007-01-30 | 2013-03-29 | Avigen Inc | Sposoby leczenia bólu ostrego |
| WO2008137012A1 (fr) * | 2007-05-03 | 2008-11-13 | Avigen, Inc. | Utilisation d'un atténuateur glial destiné à prévenir des réponses de douleurs amplifiées provoquées par un amorçage glial |
| US20090074740A1 (en) * | 2007-05-14 | 2009-03-19 | Noah Berkowitz | Use of haptoglobin genotyping in diagnosis and treatment of defective reverse cholesterol transport (RCT) |
| WO2009021113A1 (fr) * | 2007-08-09 | 2009-02-12 | Holtzman, Jordan, L. | Procédés de stimulation de l'activité de la glutathion peroxydase |
| EP2070520A1 (fr) | 2007-12-11 | 2009-06-17 | LEK Pharmaceuticals D.D. | Composition pharmaceutique comportant au moins un agent actif et un liant, qui gonfle dans un support acide |
| US10894787B2 (en) | 2010-09-22 | 2021-01-19 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
| EP2626351A4 (fr) * | 2010-10-04 | 2014-03-12 | Kowa Co | Agent capable d'inhiber l'expression d'un arnm lié au métabolisme lipidique |
| CA2845284C (fr) | 2011-08-18 | 2018-03-06 | Dr. Reddy's Laboratories Ltd. | Composes amines heterocycliques substitues comme inhibiteurs de la proteine de transfert d'ester cholesterylique (cetp) |
| EP2760864B1 (fr) | 2011-09-27 | 2018-01-24 | Dr. Reddy's Laboratories Ltd. | DÉRIVÉS DE 5-BENZYLAMINOMÉTHYL-6-AMINOPYRAZOLO[3,4-b]PYRIDINE COMME INHIBITEURS DE LA CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) UTILES POUR LE TRAITEMENT DE L'ATHÉROSCLÉROSE |
| EP4218765A3 (fr) * | 2014-08-28 | 2023-08-09 | NewAmsterdam Pharma B.V. | Composition pharmaceutique et combinaison thérapeutique comprenant un inhibiteur de la protéine de transfert de l'ester de cholestéryle et des inhibiteurs de la hmg coa réductase |
| MX2021011472A (es) | 2015-01-06 | 2022-08-17 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
| KR102603199B1 (ko) | 2015-06-22 | 2023-11-16 | 아레나 파마슈티칼스, 인크. | Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염 |
| WO2018019911A1 (fr) * | 2016-07-27 | 2018-02-01 | Hartis-Pharma Sarl | Combinaisons thérapeutiques pour traiter les troubles des globules rouges |
| WO2018151873A1 (fr) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| CN116196314B (zh) * | 2023-05-04 | 2023-08-15 | 广州市妇女儿童医疗中心 | Ri-1或其盐在制备防治胃肠道疾病的药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6144790A (en) * | 1997-02-07 | 2000-11-07 | Bledin; Anthony G | Contact fiber optic impact sensor |
| GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
| HUP0003103A3 (en) * | 1997-08-29 | 2002-03-28 | Pfizer Prod Inc | Combination therapy comprising amlodipine and a statin compound |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| US6140342A (en) * | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| US6147090A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| CA2375372C (fr) * | 1999-05-27 | 2007-01-09 | George Chang | Promedicaments communs d'amlodipine et d'atorvastatine |
| HN2000000050A (es) * | 1999-05-27 | 2001-02-02 | Pfizer Prod Inc | Sal mutua de amlodipino y atorvastatina |
| US20030092745A1 (en) * | 2000-02-25 | 2003-05-15 | Pfizer Inc. | Combination therapy |
| US20020013334A1 (en) * | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| MXPA03001419A (es) * | 2000-08-15 | 2003-06-06 | Pfizer Prod Inc | Combinacion terapeutica de un inhibidor de la proteina de transferencia de esteres de colesterol y atorvastatina. |
| US6737430B2 (en) * | 2000-11-09 | 2004-05-18 | Pfizer, Inc. | Mutual prodrug of amlodipine and atorvastatin |
| EP1385501A2 (fr) * | 2001-04-11 | 2004-02-04 | Atherogenics, Inc. | Procedes d'accroissement des taux de cholesterol hdl du plasma et d'amelioration de la fonctionnalite hdl avec des monoesters de probucol |
| US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
-
2003
- 2003-06-10 US US10/459,683 patent/US20040053842A1/en not_active Abandoned
- 2003-06-18 CA CA002488736A patent/CA2488736A1/fr not_active Abandoned
- 2003-06-18 IL IL16532803A patent/IL165328A0/xx unknown
- 2003-06-18 KR KR1020057000061A patent/KR20050025578A/ko not_active Application Discontinuation
- 2003-06-18 BR BR0312421-5A patent/BR0312421A/pt not_active IP Right Cessation
- 2003-06-18 CN CN038155753A patent/CN1665537A/zh active Pending
- 2003-06-18 AU AU2003244921A patent/AU2003244921A1/en not_active Abandoned
- 2003-06-18 AP AP2004003189A patent/AP2004003189A0/xx unknown
- 2003-06-18 MX MXPA05000015A patent/MXPA05000015A/es not_active Application Discontinuation
- 2003-06-18 PL PL03374878A patent/PL374878A1/xx not_active Application Discontinuation
- 2003-06-18 EP EP03738394A patent/EP1519754A1/fr not_active Withdrawn
- 2003-06-18 JP JP2004519080A patent/JP2005532388A/ja not_active Withdrawn
- 2003-06-18 EA EA200401471A patent/EA200401471A1/ru unknown
- 2003-06-18 WO PCT/IB2003/002792 patent/WO2004004778A1/fr not_active Application Discontinuation
- 2003-06-18 OA OA1200400342A patent/OA12876A/en unknown
- 2003-07-01 TW TW092117985A patent/TW200401768A/zh unknown
-
2004
- 2004-11-26 ZA ZA200409582A patent/ZA200409582B/en unknown
- 2004-11-29 IS IS7570A patent/IS7570A/is unknown
- 2004-12-17 MA MA28016A patent/MA27311A1/fr unknown
- 2004-12-30 HR HR20041238A patent/HRP20041238A2/xx not_active Application Discontinuation
- 2004-12-30 EC EC2004005520A patent/ECSP045520A/es unknown
- 2004-12-30 TN TNP2004000268A patent/TNSN04268A1/fr unknown
-
2005
- 2005-01-28 NO NO20050497A patent/NO20050497L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050025578A (ko) | 2005-03-14 |
| TNSN04268A1 (fr) | 2007-03-12 |
| CN1665537A (zh) | 2005-09-07 |
| WO2004004778A1 (fr) | 2004-01-15 |
| CA2488736A1 (fr) | 2004-01-15 |
| US20040053842A1 (en) | 2004-03-18 |
| NO20050497L (no) | 2005-03-08 |
| PL374878A1 (en) | 2005-11-14 |
| ECSP045520A (es) | 2005-03-10 |
| JP2005532388A (ja) | 2005-10-27 |
| IS7570A (is) | 2004-11-29 |
| BR0312421A (pt) | 2005-04-19 |
| TW200401768A (en) | 2004-02-01 |
| OA12876A (en) | 2006-09-15 |
| AU2003244921A1 (en) | 2004-01-23 |
| EP1519754A1 (fr) | 2005-04-06 |
| MXPA05000015A (es) | 2005-04-08 |
| EA200401471A1 (ru) | 2005-06-30 |
| IL165328A0 (en) | 2006-01-15 |
| ZA200409582B (en) | 2006-08-30 |
| MA27311A1 (fr) | 2005-05-02 |
| AP2004003189A0 (en) | 2004-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20041238A2 (en) | Use of cetp inhibitors and optionally hmg coa redught hyaluronic acid formulation | |
| IL165910A0 (en) | Compositions of hyaluronic acid and methods of use | |
| PL374364A1 (en) | Use of cetp inhibitors and antihypertensive agents as well as optionally hmg coa reductase inhibitors | |
| AU2003303128A8 (en) | Inhibitors and methods of use thereof | |
| AU2003288126A1 (en) | Anthranilic acid amides and the derivatives thereof as cosmetic and pharmaceutical agents | |
| IL145346A0 (en) | Dimeric compounds and their use as inhibitors of neuraminidase | |
| EP1507756A4 (fr) | Inhibiteurs de ccr9 et utilisation de ceux-ci | |
| ZA200500680B (en) | Quinoline derivatives and their use as mycrobacterial inhibitors | |
| IL161134A0 (en) | Ester compound and medical use thereof | |
| AU2003213673A8 (en) | Pin1-modulating compounds and methods of use thereof | |
| AU2003278832A8 (en) | Optical biosensors and methods of use thereof | |
| HK1098127A1 (en) | Hydroxamic acid esters and pharmaceutical use thereof | |
| HK1079789A1 (zh) | 血管靜態毒性試劑及其使用方法 | |
| IL166108A0 (en) | Novel compounds pharmaceutical compositions containing same and methods of use for same | |
| EP1476150A4 (fr) | Carboxyfullerenes et procedes d'utilisation de ceux-ci | |
| EP1487776A4 (fr) | Composes acides et esters et procedes d'utilisation associes | |
| IL166054A0 (en) | Novel compounds pharmaceutical compositions containing same and methods of use for same | |
| PL374581A1 (en) | Diaminothiazoles and use thereof as cdk4 inhibitors | |
| EP1503749A4 (fr) | Inhibiteurs de methionine aminopeptidase-2 et procedes d'utilisation de ceux-ci | |
| AU2002337913A1 (en) | Glycosulfopeptide inhibitors and methods of use thereof | |
| AU2003215364A1 (en) | Carboxylic acid containing protective coating compositions and methods of use thereof | |
| PL373163A1 (en) | Salt of (s)-pantoprazole and its hydrates | |
| IL163959A (en) | Derivatives of phenyl-sulfonylamino- benzoic acid and pharmaceutical compositions comprising them | |
| AU2002342889A1 (en) | Anthranilic acid amides and pharmaceutical use thereof | |
| IL161163A0 (en) | Anthranilic acid amides and pharmaceutical use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20060608 Year of fee payment: 4 |
|
| OBST | Application withdrawn |